ES2300349T3 - Compuestos de barbiturato no sedantes como agentes neuroprotectores. - Google Patents

Compuestos de barbiturato no sedantes como agentes neuroprotectores. Download PDF

Info

Publication number
ES2300349T3
ES2300349T3 ES01959195T ES01959195T ES2300349T3 ES 2300349 T3 ES2300349 T3 ES 2300349T3 ES 01959195 T ES01959195 T ES 01959195T ES 01959195 T ES01959195 T ES 01959195T ES 2300349 T3 ES2300349 T3 ES 2300349T3
Authority
ES
Spain
Prior art keywords
barbiturate
sedating
ischemia
dose
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES01959195T
Other languages
English (en)
Spanish (es)
Inventor
Daniel A. Moros
Barrie Levitt
Avraham Yacobi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taro Pharmaceutical Industries Ltd
Original Assignee
Taro Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taro Pharmaceutical Industries Ltd filed Critical Taro Pharmaceutical Industries Ltd
Application granted granted Critical
Publication of ES2300349T3 publication Critical patent/ES2300349T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ES01959195T 2000-07-26 2001-07-26 Compuestos de barbiturato no sedantes como agentes neuroprotectores. Expired - Lifetime ES2300349T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22167200P 2000-07-26 2000-07-26
US221672P 2000-07-26

Publications (1)

Publication Number Publication Date
ES2300349T3 true ES2300349T3 (es) 2008-06-16

Family

ID=22828824

Family Applications (1)

Application Number Title Priority Date Filing Date
ES01959195T Expired - Lifetime ES2300349T3 (es) 2000-07-26 2001-07-26 Compuestos de barbiturato no sedantes como agentes neuroprotectores.

Country Status (14)

Country Link
EP (1) EP1311270B1 (US07794700-20100914-C00152.png)
JP (1) JP5047442B2 (US07794700-20100914-C00152.png)
CN (2) CN1329032C (US07794700-20100914-C00152.png)
AT (1) ATE383159T1 (US07794700-20100914-C00152.png)
AU (2) AU2001280778B2 (US07794700-20100914-C00152.png)
BR (1) BR0112775A (US07794700-20100914-C00152.png)
CA (1) CA2416535C (US07794700-20100914-C00152.png)
DE (1) DE60132337T2 (US07794700-20100914-C00152.png)
ES (1) ES2300349T3 (US07794700-20100914-C00152.png)
HK (1) HK1100814A1 (US07794700-20100914-C00152.png)
IL (3) IL154060A0 (US07794700-20100914-C00152.png)
MX (1) MXPA03000824A (US07794700-20100914-C00152.png)
PT (1) PT1311270E (US07794700-20100914-C00152.png)
WO (1) WO2002007729A1 (US07794700-20100914-C00152.png)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6093820A (en) 1997-10-02 2000-07-25 Taro Pharmaceutical Industries Ltd. Method and reagents for N-alkylating ureides
EP1311270B1 (en) * 2000-07-26 2008-01-09 Taro Pharmaceutical Industries Limited Non-sedating barbiturate compounds as neuroprotective agents
US6756379B2 (en) 2001-07-26 2004-06-29 Taro Pharmaceutical Industries Ltd. Non-sedating barbiturate compounds as neuroprotective agents
US7683071B2 (en) 2000-07-26 2010-03-23 Taro Pharmaceuticals Industries Ltd. Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid
US6939873B2 (en) 2000-07-26 2005-09-06 Taro Pharmaceuticals Industries Limited Non-sedating barbituric acid derivatives
CN1291720C (zh) * 2002-01-30 2006-12-27 塔罗制药工业有限公司 非镇静性巴比土酸衍生物
KR101403264B1 (ko) * 2002-10-11 2014-06-02 백스터 인터내셔널 인코포레이티드 할로겐화된 휘발성 마취제의 정맥내 투여에 의한 심장보호 및 신경보호방법
AR042444A1 (es) * 2002-12-11 2005-06-22 Taro Pharmaceuticals Ireland L Metodo para el tratamiento de desordenes del movimiento mediante la utilizacion de acido barbiturico
EP1625848A1 (en) * 2004-08-10 2006-02-15 Taro Pharmaceuticals North America, Inc. Composition and method for enhanced delivery of 5,5-diphenyl barbituric acid
US9056817B2 (en) * 2011-09-12 2015-06-16 Council Of Scientific And Industrial Research Arylated β-dicarbonyl compounds and process for the preparation thereof
CN102863579B (zh) * 2012-09-14 2014-02-05 东南大学 一种巴比妥酸螯合树脂及其制备方法和应用
CN113640512A (zh) 2015-10-05 2021-11-12 北卡罗来纳-查佩尔山大学 用于多路测定的解码方法及相关流体设备、试剂盒和固体支持物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL69722A (en) * 1983-09-14 1986-09-30 Taro Pharma Ind Oxopyrimidine derivatives and pharmaceutical compositions containing them
US4833148A (en) * 1987-04-09 1989-05-23 Washington University Method of using alkenyl- or alkynyl-substituted thiobarbiturates to reduce neurotoxic injury
US5474990A (en) * 1989-10-20 1995-12-12 Olney; John W. Barbiturates as safening agents in conjunction with NMDA antagonists
EP1311270B1 (en) * 2000-07-26 2008-01-09 Taro Pharmaceutical Industries Limited Non-sedating barbiturate compounds as neuroprotective agents

Also Published As

Publication number Publication date
IL154060A (en) 2013-05-30
ATE383159T1 (de) 2008-01-15
CA2416535A1 (en) 2002-01-31
PT1311270E (pt) 2008-04-15
CN100522172C (zh) 2009-08-05
AU2001280778B2 (en) 2004-09-02
WO2002007729A9 (en) 2002-08-08
EP1311270A1 (en) 2003-05-21
EP1311270B1 (en) 2008-01-09
EP1311270A4 (en) 2006-04-12
CA2416535C (en) 2010-11-16
CN1872067A (zh) 2006-12-06
AU8077801A (en) 2002-02-05
CN1329032C (zh) 2007-08-01
HK1100814A1 (en) 2007-09-28
BR0112775A (pt) 2003-12-30
JP5047442B2 (ja) 2012-10-10
MXPA03000824A (es) 2004-11-01
IL154060A0 (en) 2003-07-31
DE60132337D1 (de) 2008-02-21
IL165017A0 (en) 2005-12-18
DE60132337T2 (de) 2009-02-12
JP2004517808A (ja) 2004-06-17
WO2002007729A1 (en) 2002-01-31
CN1461219A (zh) 2003-12-10

Similar Documents

Publication Publication Date Title
CN108348492B (zh) 使用谷氨酰胺类似物的用于癌症和免疫疗法的方法
US7396825B2 (en) Agonists of A2A adenosine receptors for treatment of diabetic nephropathy
US8158639B2 (en) Non-sedating barbiturate compounds as neuroprotective agents
ES2300349T3 (es) Compuestos de barbiturato no sedantes como agentes neuroprotectores.
ES2435799T3 (es) Un método de inhibición del virus de la hepatitis C mediante combinación de una 5,6-dihidro-1H-piridin-2-ona y de uno o más compuestos antivirales adicionales
JP2021091690A (ja) 急性骨髄性白血病（ａｍｌ）のための新規併用治療
Paul et al. Adenosine A1 receptors in the central nervous system: their functions in health and disease, and possible elucidation by PET imaging
US20080262001A1 (en) Agonists of a2a adenosine receptors for treating recurrent tumor growth in the liver following resection
TW200418460A (en) Methods of using and compositions comprising a JNK inhibitor for the treatment, prevention, management and/or modification of pain
ES2903136T3 (es) Clorhidrato de creatina para el tratamiento de la enfermedad de Huntington
AU2001280778A1 (en) Non-sedating barbiturate compounds as neuroprotective agents
CN118652215A (zh) Atp合酶反向模式的治疗性调节剂
US11571410B2 (en) Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder
Tanaka et al. Antidepressant-like Effects of Kynurenic Acid Analogues
KR20170131241A (ko) 삼차신경통을 예방 또는 치료하기 위한 카바메이트 화합물의 용도
ES2952672T3 (es) Tratamiento del dolor neuropático asociado a la neuropatía periférica inducida por la quimioterapia
ES2318036T3 (es) Farmacos que comprenden una combinacion de un agente antitrombotico con un derivado de pirazolona.
AU2007200460B2 (en) Non-sedating barbiturate compounds as neuroprotective agents
AU2004229086C1 (en) Non-sedating barbiturate compounds as neuroprotective agents
JP2005516052A (ja) 非鎮静性バルビツール酸誘導体
ES2317913T3 (es) Tratamiento antitumoral combinado que comprende un derivado de la distamicina sustituida por acriloilo y un antimetabolito.
ES2881863T3 (es) Métodos para tratar cáncer usando terapia de combinación de inhibidor de quinasa TOR con un inhibidor de histona desacetilasa
KR20190087570A (ko) 가려움증의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도
EA032217B1 (ru) Новое сочетание 3-[(3-{[4-(4-морфолинилметил)-1h-пиррол-2-ил]метилен}-2-оксо-2,3-дигидро-1h-индол-5-ил)метил]-1,3-тиазолидин-2,4-диона и ингибитора тирозинкиназы egfr
ES2832549T3 (es) Composiciones y métodos para tratar la esclerosis lateral amiotrófica en respondedores